The Day In Review: Urigen Inc. Uses Valentis, Inc. For Reverse Merger

October 6, 2006 -- Valentis will be bought as part of a reverse merger by privately held Urigen; Wyeth filed for marketing approval of a renal cell carcinoma drug in the US and Europe; Schering-Plough won marketing approval in Europe for Suboxone, a treatment for opioid dependence; deCODE genetics is suspending a trial of an anti-heart attack medication because of a manufacturing problem; Chattem bought US rights to five leading OTC medications from Johnson & Johnson; and Genta completed a Special Protocol Assessment with the FDA for Genasense. The Centient Biotech 200™ rose a fraction of a point to 3898.09, a positive move of just .01%. More details...